Log in

1672 Ascletis Pharma, Inc. HKEX · China

Ascletis Pharma (1672) news

Ascletis Pharma, Inc. is a public biotech or pharmaceutical company listed on HKEX under the ticker 1672, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Ascletis Pharma news

We have not published a story on Ascletis Pharma yet. When there is news, it will appear here.

Questions about Ascletis Pharma

What is the ticker symbol of Ascletis Pharma?

Ascletis Pharma, Inc. trades under the ticker 1672 on HKEX.

Where is Ascletis Pharma listed?

Ascletis Pharma, Inc. is listed on HKEX. Our directory also records these other listings: GETTEX:2VJ; LSX:A2JRKN; OTC:ASCLF.

Which country or territory is Ascletis Pharma listed under?

Our directory records Ascletis Pharma, Inc. under China.

What does Ascletis Pharma do?

Our directory classifies Ascletis Pharma, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Ascletis Pharma?

The ISIN recorded for Ascletis Pharma, Inc. is KYG0520K1094.

Does aibio.space cover Ascletis Pharma?

aibio.space lists Ascletis Pharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Ascletis Pharma?

Companies in our directory listed in the same country and business area as Ascletis Pharma: Jiangsu gdk Biotechnology Co., Shanghai Rightongene Biotechnology Co., Shanghai Obio Technology (Group) Corp., Kintor Pharmaceutical, Zhejiang Laifual Drive Co., Xiamen Amoytop Biotech Co..

Investor discussion: Ascletis Pharma

Members talk about Ascletis Pharma (1672). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Ascletis Pharma, newest first. Each line links the filing it comes from.

  1. Financings

    Share or debt issue: PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES, RE-ELECTION OF RETIRING DIRECTORS, PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION AND NOTICE OF ANNUAL GENERAL MEETING. Source

  2. Financings

    Share or debt issue: COMPLETION OF PLACING OF NEW SHARES UNDER THE GENERAL MANDATE. Source

  3. Financings

    Share or debt issue: PLACING OF NEW SHARES UNDER THE GENERAL MANDATE. Source

  4. Financings

    Share or debt issue: COMPLETION OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER THE GENERAL MANDATE. Source

  5. Financings

    Share or debt issue: (1) PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER THE GENERAL MANDATE AND (2) SALE OF SHARES BY THE TOP-UP VENDOR. Source

  6. Legal

    Legal proceedings: INSIDE INFORMATION - FINAL JUDGMENT ON LEGAL PROCEEDINGS INVOLVING ASC41 AND ASC43F. Source

  7. Financings

    Share or debt issue: PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES, RE-ELECTION OF RETIRING DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING. Source

Press releases

Headlines of Ascletis Pharma's own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. PR Newswire

    Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase II Study in Participants with Diabetes

  2. HKEXnews

    VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES FDA IND SUBMISSION OF ASC39, AN ORAL SMALL MOLECULE SELECTIVE AMYLIN RECEPTOR AGONIST FOR THE TREATMENT OF OBESITY

  3. HKEXnews

    VOLUNTARY ANNOUNCEMENT - ASCLETIS' STRATEGIC PARTNER SAGIMET ANNOUNCES FIRST PATIENT DOSED IN PHASE III U.S. CLINICAL TRIAL OF DENIFANSTAT (ASC40) FOR MODERATE TO SEVERE ACNE

  4. HKEXnews

    VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES POSITIVE PRECLINICAL DATA FOR THE MOST COMPREHENSIVE ONCE-WEEKLY ORAL PEPTIDE PIPELINE FOR THE TREATMENT OF OBESITY

  5. HKEXnews

    VOLUNTARY ANNOUNCEMENT - ASCLETIS' ASC36_35FDC DEMONSTRATED POTENTIAL FOR ONCE-MONTHLY TO ONCE-QUARTERLY DOSING AND ROBUST WEIGHT-LOSS IN PRECLINICAL STUDIES PRESENTED AT EASD 2026

  6. HKEXnews

    VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES POSITIVE RESULTS FROM 28-DAY PROOF-OF-CONCEPT CLINICAL STUDY IN U.S. FOR ASC50, A FIRST-IN-CLASS AND BEST-IN-CLASS ORAL SMALL MOLECULE IL-17A INHIBITOR FOR THE TREATMENT OF PLAQUE PSORIASIS

  7. HKEXnews

    VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES INITIATION OF PHASE I STUDY IN U.S. FOR ORAL AMYLIN RECEPTOR PEPTIDE AGONIST ASC36 FOR THE TREATMENT OF OBESITY

  8. HKEXnews

    VOLUNTARY ANNOUNCEMENT - INCLUSION IN THE HONG KONG STOCK CONNECT LIST UNDER THE SHANGHAI-HONG KONG STOCK CONNECT AND THE SHENZHEN-HONG KONG STOCK CONNECT PROGRAMS

  9. HKEXnews

    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

  10. HKEXnews

    VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES FIRST PARTICIPANT DOSED IN A GLOBAL PHASE III CLINICAL PROGRAM OF ONCE-DAILY ORAL SMALL MOLECULE GLP-1 RECEPTOR AGONIST ASC30 FOR CHRONIC WEIGHT MANAGEMENT

  11. HKEXnews

    PROFIT WARNING

  12. HKEXnews

    VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES INITIATION OF TWO PHASE I STUDIES IN U.S. FOR THE TREATMENT OF OBESITY: ASC36 ONCE-MONTHLY INJECTION, AN AMYLIN RECEPTOR PEPTIDE AGONIST, AND ASC36_35FDC ONCE-MONTHLY INJECTION, A CO-FORMULATION OF ASC36 AND GLP-1R/GIPR PEPTIDE AGONIST ASC35

  13. HKEXnews

    VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES INITIATION OF GLOBAL PHASE III FOR ORAL SMALL MOLECULE GLP-1, ASC30 AND POSITIVE PRECLINICAL DATA FOR ITS FIRST-IN-CLASS ORAL SMALL MOLECULE GLP-1/GIP/AMYLIN FIXED-DOSE COMBINATION

  14. HKEXnews

    VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES ONCE-MONTHLY SUBCUTANEOUSLY ADMINISTERED GLP-1R/GIPR/GCGR TRIPLE PEPTIDE AGONIST, ASC37, DEMONSTRATED SUPERIOR WEIGHT LOSS IN A DIET-INDUCED OBESE MOUSE MODEL

  15. HKEXnews

    VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES ORAL DISCUSSION OF ASC36_35 FDC PRECLINICAL DATA DEMONSTRATING SUPERIOR WEIGHT LOSS TO ELORALINTIDE/TIRZEPATIDE COMBINATION AT THE 62ND EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD) ANNUAL MEETING

  16. HKEXnews

    VOLUNTARY ANNOUNCEMENT - ASCLETIS SELECTS FOR CLINICAL DEVELOPMENT A FIXED-DOSE COMBINATION OF FIRST-IN-CLASS ORAL SMALL MOLECULE GIPR AGONIST, ASC48, AND ORAL SMALL MOLECULE GLP-1R AGONIST, ASC30

  17. HKEXnews

    VOLUNTARY ANNOUNCEMENT - ASCLETIS SUBMITS TWO IND APPLICATIONS TO THE U.S. FDA FOR THE TREATMENT OF OBESITY: ASC36 ONCE-MONTHLY INJECTION, A PEPTIDE AMYLIN RECEPTOR AGONIST, AND ASC36_35 FDC ONCE-MONTHLY INJECTION, A CO-FORMULATION OF ASC36 PLUS PEPTIDE GLP-1R/GIPR AGONIST ASC35

  18. HKEXnews

    VOLUNTARY ANNOUNCEMENT - PROPOSED SHARE REPURCHASE UNDER THE REPURCHASE MANDATE

  19. HKEXnews

    THIRD AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION

  20. HKEXnews

    POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 29, 2026

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:1672 on TradingView.

Listing details

Ascletis Pharma, Inc. is a public biotech or pharmaceutical company listed on HKEX under the ticker 1672, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Ascletis Pharma, Inc.
Ticker
1672
Listing
HKEX
Country or territory
China
Business scope
Biotechnology
ISIN
KYG0520K1094
Other listed symbols
GETTEX:2VJ; LSX:A2JRKN; OTC:ASCLF
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.